- Home
- CTO vs CERS Comparison
CTO vs CERS Comparison
Compare CTO & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | CERS |
|---|---|---|
| Founded | 1902 | 1991 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | EDP Services |
| Sector | Real Estate | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.9M | 585.1M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | CTO | CERS |
|---|---|---|
| Price | $22.16 | $3.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | 323.0K | ★ 2.4M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $7.63 | $19.95 |
| Revenue Next Year | $2.76 | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $15.07 | $1.15 |
| 52 Week High | $22.66 | $3.47 |
Technical Indicators
Market Signals| Indicator | CTO | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 60.41 | 55.75 |
| Support Level | $17.79 | $2.92 |
| Resistance Level | $22.66 | $3.19 |
| Average True Range (ATR) | 0.40 | 0.15 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 73.14 | 59.39 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.